It was the mid-1990s. The incident involved a self-service counter and one bowl that contained hidden nuts.
Adam was 10 years old. I was older, but still at school. I remember the nurse coming into my classroom to say Adam had been taken to hospital and I should make my own way home. My dad phoned me when I got there, trying to reassure me that everyone would be home soon. But knowing he must have raced back early from work, I felt uneasy.
Founded in February 2014, 4D Pharma (LON:DDDD) is a world leader in the development of live biotherapeutics, a novel and emerging class of drugs, defined by the FDA as biological products that contain a live organism, such as a bacteria, that is applicable to the prevention, treatment or cure of a disease. 4D has developed a proprietary platform that rationally identifies novel bacteria that have a precise and evolved therapeutic effect. All of 4D’s live biotherapeutic products are orally delivered single strains of bacteria that are naturally found in the healthy human gut. 4D has completed a phase I study in Irritable Bowel Syndrome and has completed dosing in a phase I study in Paediatric Crohn’s Disease. It currently has a pipeline of 13 pre-clinical programmes, covering disease areas such as cancer, poorly controlled asthma, autoimmune and CNS disease, and plans to commence four additional clinical studies in 2018.
